Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion type Assertion NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_head.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion wasGeneratedBy ECO_0000203 NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_provenance.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion wasDerivedFrom befree-2016 NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_provenance.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion SIO_000772 22123186 NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_provenance.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion evidence source_evidence_literature NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_provenance.
- NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_assertion description "[The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP942329.RAtSWDE0bL-773oUjVXeLoATHUxxoORwR5srJDcEqTWeI130_provenance.